Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844228 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
A Phase 1 study, sponsored by Vir Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05844228: Completed Phase 1 study, sponsored by Vir Biotechnology.
NCT05844228 is a Phase 1 study that has completed, run by Vir Biotechnology. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05844228, a Phase 1 study, has completed, sponsored by Vir Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
Interventions
- DRUG VIR-2218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 1 |
What the finished NCT05844228 record still lists
NCT05844228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which VIR-2218 is the first listed.
NCT05844228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05844228 about?
NCT05844228 is a clinical study titled "A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218". The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
What is the current status of trial NCT05844228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-06-01. Estimated completion is 2025-04-21.
What interventions are being tested in trial NCT05844228?
The interventions under investigation include: VIR-2218 (DRUG).
Who is sponsoring clinical trial NCT05844228?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05844228's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI